Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6765) 6765
Publication (924) 924
Book Chapter (34) 34
Book Review (23) 23
Dissertation (22) 22
Conference Proceeding (17) 17
Book / eBook (4) 4
Magazine Article (3) 3
Paper (2) 2
Web Resource (2) 2
Data Set (1) 1
Government Document (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4343) 4343
index medicus (4140) 4140
female (3967) 3967
breast cancer (3835) 3835
oncology (3058) 3058
triple negative breast neoplasms - pathology (2183) 2183
triple-negative breast cancer (2006) 2006
middle aged (1679) 1679
cancer (1651) 1651
cell line, tumor (1517) 1517
prognosis (1488) 1488
adult (1387) 1387
triple negative breast neoplasms - genetics (1384) 1384
metastasis (1377) 1377
triple negative breast neoplasms - metabolism (1343) 1343
triple negative breast neoplasms - drug therapy (1299) 1299
chemotherapy (1286) 1286
expression (1280) 1280
aged (1202) 1202
triple negative breast cancer (1168) 1168
tumors (1119) 1119
animals (1077) 1077
breast neoplasms - pathology (969) 969
survival (928) 928
gene expression (827) 827
analysis (824) 824
apoptosis (809) 809
mice (807) 807
research (770) 770
breast neoplasms - metabolism (746) 746
immunohistochemistry (723) 723
cell biology (705) 705
care and treatment (670) 670
health aspects (637) 637
article (634) 634
gene expression regulation, neoplastic (633) 633
cancer therapies (621) 621
therapy (596) 596
receptor, erbb-2 - metabolism (592) 592
medical prognosis (583) 583
carcinoma (581) 581
genetic aspects (570) 570
cells (569) 569
medicine & public health (561) 561
triple negative (555) 555
breast (548) 548
receptors, estrogen - metabolism (542) 542
proteins (524) 524
subtypes (517) 517
neoplasm staging (510) 510
disease-free survival (503) 503
aged, 80 and over (484) 484
breast neoplasms - genetics (476) 476
pathology (475) 475
triple negative breast neoplasms - mortality (465) 465
receptors, progesterone - metabolism (456) 456
treatment outcome (454) 454
cell proliferation - drug effects (452) 452
breast neoplasms - drug therapy (447) 447
growth (447) 447
estrogen (445) 445
research article (434) 434
antineoplastic agents - pharmacology (431) 431
development and progression (430) 430
retrospective studies (425) 425
biochemistry & molecular biology (406) 406
cell proliferation (405) 405
mutation (404) 404
epidermal growth factor (399) 399
phenotype (398) 398
xenograft model antitumor assays (397) 397
neoadjuvant chemotherapy (394) 394
signal transduction (386) 386
antineoplastic combined chemotherapy protocols - therapeutic use (378) 378
biomarkers, tumor - metabolism (372) 372
medicine (368) 368
metastases (367) 367
antineoplastic agents - therapeutic use (361) 361
triple negative breast neoplasms - therapy (360) 360
apoptosis - drug effects (351) 351
identification (346) 346
kinases (343) 343
kaplan-meier estimate (342) 342
activation (338) 338
biomarkers (337) 337
women (336) 336
risk factors (335) 335
skin and connective tissue diseases (335) 335
patients (334) 334
surgery (330) 330
research paper (329) 329
proliferation (328) 328
breast neoplasms - mortality (326) 326
studies (325) 325
medicine, research & experimental (320) 320
inhibition (319) 319
epithelial-mesenchymal transition (313) 313
estrogen-receptor (312) 312
cancer research (311) 311
mice, nude (308) 308
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6602) 6602
Chinese (54) 54
French (52) 52
Japanese (31) 31
Spanish (25) 25
Russian (22) 22
German (17) 17
Czech (8) 8
Korean (7) 7
Polish (7) 7
Portuguese (3) 3
Bulgarian (1) 1
Croatian (1) 1
Hungarian (1) 1
Latvian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


41. Full Text Prognostic significance of p16 & p53 immunohistochemical expression in triple negative breast cancer 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis
by Ali Hashmi, Atif and Naz, Samreen and Hashmi, Shumaila Kanwal and Hussain, Zubaida Fida and Irfan, Muhammad and Khan, Erum Yousuf and Faridi, Naveen and Khan, Amir and Edhi, Muhammad Muzzammil
BMC Clinical Pathology, 10/2018, Volume 18, Issue 1
p16 | Triple negative breast cancer | p53
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
42. Full Text Splenic Marginal Zone Lymphoma with Prominent Myelofibrosis Mimicking Triple-Negative Primary Myelofibrosis
by Tsutsui, Miyuki and Yasuda, Hajime and Ota, Yasunori and Komatsu, Norio
Case Reports in Oncology, ISSN 1662-6575, 11/2019, Volume 12, Issue 3, pp. 834 - 837
Myelofibrosis (MF) can occur due to a wide variety of causes including malignant lymphoma. We report a case of splenic marginal zone lymphoma complicated by MF... 
pmf | smzl | differential diagnosis | triple-negative | jak2
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
43. Full Text Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199
by Adams, Sylvia and Gray, Robert J and Demaria, Sandra and Goldstein, Lori and Perez, Edith A and Shulman, Lawrence N and Martino, Silvana and Wang, Molin and Jones, Vicky E and Saphner, Thomas J and Wolff, Antonio C and Wood, William C and Davidson, Nancy E and Sledge, George W and Sparano, Joseph A and Badve, Sunil S
Journal of Clinical Oncology, ISSN 0732-183X, 09/2014, Volume 32, Issue 27, pp. 2959 - 2966
Purpose Recent studies suggest that tumor-infiltrating lymphocytes (TILs) are associated with disease-free (DFS) and overall survival (OS) in operable... 
CELLS | ONCOLOGY | ESTROGEN-RECEPTOR | CHEMOTHERAPY | Predictive Value of Tests | Reproducibility of Results | Prognosis | Biomarkers, Tumor - analysis | Humans | Middle Aged | Kaplan-Meier Estimate | Triple Negative Breast Neoplasms - drug therapy | Randomized Controlled Trials as Topic | Disease-Free Survival | Clinical Trials, Phase III as Topic | Lymphocytes, Tumor-Infiltrating - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Triple Negative Breast Neoplasms - pathology | Aged, 80 and over | Adult | Female | Aged | Retrospective Studies | Chemotherapy, Adjuvant | Bc2 | Bios4 | Bc5 | ORIGINAL REPORTS | Bc8
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
44. Full Text Higher levels of TIMP-1 expression are associated with a poor prognosis in triplenegative breast cancer
by Cheng, Guangcun and Fan, Xuemei and Hao, Mingang and Wang, Jinglong and Zhou, Xiaoming and Sun, Xueqing
Molecular Cancer, 2016, Volume 15, Issue 1
TIMP-1 | Poor prognosis | G1 phase | Triple-negative breast cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
45. Full Text Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers
by Denkert, Carsten and Von Minckwitz, Gunter and Brase, Jan C and Sinn, Bruno V and Gade, Stephan and Kronenwett, Ralf and Pfitzner, Berit M and Salat, Christoph and Loi, Sherene and Schmitt, Wolfgang D and Schem, Christian and Fisch, Karin and Darb-Esfahan, Silvia and Mehta, Keyur and Sotiriou, Christos and Wienert, Stephan and Klare, Peter and André, Fabrice and Klauschen, Frederick and Blohmer, Jens-Uwe and Krappmann, Kristin and Schmidt, Marcus and Tesch, Hans and Kümmel, Sherko and Sinn, Peter and Jackisch, Christian and Dietel, Manfred and Reimer, Toralf and Untch, Michael and Loibl, Sibylle
Journal of Clinical Oncology, ISSN 0732-183X, 04/2015, Volume 33, Issue 9, pp. 983 - 991
Purpose Modulation of immunologic interactions in cancer tissue is a promising therapeutic strategy. To investigate the immunogenicity of human epidermal... 
SURVIVAL | MULTICENTER | TRASTUZUMAB | ONCOLOGY | MARKER | SAFETY | OPEN-LABEL | EXPRESSION | PHASE-2 TRIAL | Predictive Value of Tests | Prognosis | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Receptor, ErbB-2 - metabolism | Carboplatin - administration & dosage | Antineoplastic Agents - therapeutic use | Triple Negative Breast Neoplasms - drug therapy | Randomized Controlled Trials as Topic | Chemotherapy, Adjuvant - methods | Triple Negative Breast Neoplasms - metabolism | Neoadjuvant Therapy - methods | Biomarkers, Tumor - metabolism | Adult | Female | Lymphocytes, Tumor-Infiltrating - metabolism | Aged
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
46. Full Text Impact of homologous recombination deficiency biomarkers on outcomes in patients with triplenegative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313)
by Sharma, P and Barlow, W.E and Godwin, A.K and Pathak, H and Isakova, K and Williams, D and Timms, K.M and Hartman, A.R and Wenstrup, R.J and Linden, H.M and Tripathy, D and Hortobagyi, G.N and Hayes, D.F
Annals of Oncology, ISSN 0923-7534, 03/2018, Volume 29, Issue 3, pp. 654 - 660
Biomarker | Chemotherapy | Homologous recombination deficiency (HRD) | BRCA mutation | Triple negative breast cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
47. Full Text Clonal evolution in breast cancer revealed by single nucleus genome sequencing
by Wang, Yong and Waters, Jill and Leung, Marco L and Unruh, Anna and Roh, Whijae and Shi, Xiuqing and Chen, Ken and Scheet, Paul and Vattathil, Selina and Liang, Han and Multani, Asha and Zhang, Hong and Zhao, Rui and Michor, Franziska and Meric-Bernstam, Funda and Navin, Nicholas E
Nature, ISSN 0028-0836, 08/2014, Volume 512, Issue 7513, pp. 155 - 160
Sequencing studies of breast tumour cohorts have identified many prevalent mutations, but provide limited insight into the genomic diversity within tumours.... 
HETEROGENEITY | REARRANGEMENT | NUCLEOTIDE | EXPRESS | MULTIDISCIPLINARY SCIENCES | GROWTH-RATE | CARCINOMAS | PATTERNS | HYBRIDIZATION | MUTATIONS | Models, Theoretical | DNA Fingerprinting | Humans | Genome - genetics | Mutation - genetics | Sequence Analysis, DNA | Genetic Variation | Breast Neoplasms - genetics | Triple Negative Breast Neoplasms - genetics | Cell Line, Tumor | Female | Single-Cell Analysis | Clonal Evolution | Care and treatment | Patient outcomes | Estrogen | Development and progression | Breast cancer | Genetic aspects | Genomes | Research | Nucleotide sequencing | DNA sequencing | Medical research | Mutation | Chromosomes | Genomics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
48. Full Text Dynamin 2, cell trafficking, and the triple-negative paradox
by Chernikova, Sophia B and Game, John C and Brown, J Martin
Oncotarget, ISSN 1949-2553, 03/2019, Volume 10, Issue 24, p. 2336
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
49. Full Text The combination of PD-L1 expression and decreased tumorinfiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer
by Mori, Hitomi and Kubo, Makoto and Yamaguchi, Rin and Nishimura, Reiki and Osako, Tomofumi and Arima, Nobuyuki and Okumura, Yasuhiro and Okido, Masayuki and Yamada, Mai and Kai, Masaya and Kishimoto, Junji and Oda, Yoshinao and Nakamura, Masafumi
Oncotarget, 2017, Volume 8, Issue 9, pp. 15584 - 15592
Biomarker | Programmed cell death ligand-1 | Prognosis | Tumor-infiltrating lymphocytes | Triple-negative breast cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
50. Estrogen, progesterone and HER2 receptor expression in breast tumors of patients, and their usage of HER2-targeted therapy, in a tertiary care centre in India
by Ghosh, J and Gupta, S and Desai, S and Shet, T and Radhakrishnan, S and Suryavanshi, P and Parmar, V and Jalali, R and Goyal, G and Hawaldar, R and Patil, A and Nair, N and Badwe, R A
04/2012
Background: This study was undertaken to document the pattern of expression of estrogen (ER), progesterone (PR) and human epidermal growth factor receptor-2... 
HER2-targeted therapy | triple negative | India
Web Resource
Details down arrow
51. Full Text Targeting themolecular subtypes of triple negative breast cancer: Understanding the diversity to progress the field
by Yam, Clinton and Mani, Sendurai A and Moulder, Stacy L
Oncologist, ISSN 1083-7159, 09/2017, Volume 22, Issue 9, pp. 1086 - 1093
Molecular subtypes | Gene expression profiling | Targeted therapy | Triple negative breast cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
52. Full Text FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer
by Oliveira, M and Saura, C and Nuciforo, P and Calvo, I and Andersen, J and Passos-Coelho, J L and Gil Gil, M and Bermejo, B and Patt, D A and Ciruelos, E and de la Peña, L and Xu, N and Wongchenko, M and Shi, Z and Singel, S M and Isakoff, S J
Annals of Oncology, ISSN 0923-7534, 08/2019, Volume 30, Issue 8, pp. 1289 - 1297
Abstract Background This hypothesis-generating trial evaluated neoadjuvant ipatasertib–paclitaxel for early triple-negative breast cancer (TNBC). Patients and... 
neoadjuvant | triple-negative breast cancer | CARBOPLATIN | PI3K | ONCOLOGY | ipatasertib | PTEN | AKT INHIBITOR
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
53. Full Text miR‐483‐3p suppresses the proliferation and progression of human triple negative breast cancer cells by targeting the HDAC8>oncogene
by Menbari, Mohammad‐Nazir and Rahimi, Karim and Ahmadi, Abbas and Mohammadi‐Yeganeh, Samira and Elyasi, Anvar and Darvishi, Nikoo and Hosseini, Vahedeh and Abdi, Mohammad
Journal of Cellular Physiology, ISSN 0021-9541, 03/2020, Volume 235, Issue 3, pp. 2631 - 2642
Triple negative breast cancer (TNBC) is a heterogeneous subclass of breast cancer (BC) distinguished by lack of hormone receptor expression. It is highly... 
triple negative breast cancer | miR‐483‐3p | cancer progression | HDAC8
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
54. Full Text Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxanebased chemotherapy
by Darb-Esfahani, Silvia and Denkert, Carsten and Stenzinger, Albrecht and Salat, Christoph and Sinn, Bruno and Schem, Christian and Endris, Volker and Klare, Peter and Schmitt, Wolfgang and Blohmer, Jens-Uwe and Weichert, Wilko and Möbs, Markus and Tesch, Hans and Kümmel, Sherko and Sinn, Peter and Jackisch, Christian and Dietel, Manfred and Reimer, Toralf and Loi, Sherene and Untch, Michael and von Minckwitz, Gunter and Nekljudova, Valentina and Loibl, Sibylle
Oncotarget, 2016, Volume 7, Issue 42, pp. 67686 - 67698
Pathological complete response | Mutation | HER2 | TP53 | Triple negative breast cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
55. Full Text Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
by Schmid, Peter and Adams, Sylvia and Rugo, Hope S and Schneeweiss, Andreas and Barrios, Carlos H and Iwata, Hiroji and Diéras, Véronique and Hegg, Roberto and Im, Seock-Ah and Shaw Wright, Gail and Henschel, Volkmar and Molinero, Luciana and Chui, Stephen Y and Funke, Roel and Husain, Amreen and Winer, Eric P and Loi, Sherene and Emens, Leisha A and IMpassion 130 Trial Investigators and IMpassion130 Trial Investigators
The New England Journal of Medicine, ISSN 0028-4793, 11/2018, Volume 379, Issue 22, pp. 2108 - 2121
Addition of the anti–PD-L1 antibody atezolizumab to nab-paclitaxel as first-line therapy for patients with advanced or metastatic triple-negative breast cancer... 
TUMOR-INFILTRATING LYMPHOCYTES | SURVIVAL | MEDICINE, GENERAL & INTERNAL | ANTI-PD-L1 ANTIBODY | PREDICTIVE-VALUE | EXPRESSION | CHEMOTHERAPY | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Paclitaxel - adverse effects | Albumins - administration & dosage | Triple Negative Breast Neoplasms - mortality | Triple Negative Breast Neoplasms - drug therapy | Albumins - adverse effects | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Progression-Free Survival | Intention to Treat Analysis | Survival Analysis | Triple Negative Breast Neoplasms - pathology | Adult | Female | Aged | Paclitaxel - administration & dosage | Liver | Breast cancer | Metastasis | Cancer therapies | Survival | ErbB-2 protein | Metastases | Nanoparticles | Chemotherapy | Epidermal growth factor | Motivation | Immunotherapy | PD-L1 protein | Paclitaxel | Data collection | Antitumor activity | Death | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
56. Full Text A nomogram prediction for the survival of patients with triple negative breast cancer
by Lin, Yuxiang and Fu, Fangmeng and Lin, Songping and Qiu, Wei and Zhou, Wei and Lv, Jinxing and Wang, Chuan
Oncotarget, ISSN 1949-2553, 08/2018, Volume 9, Issue 63, pp. 32108 - 32118
Triple negative breast cancer (TNBC) is a subtype of breast cancer with poor prognosis. In this study, we aimed to conduct a nomogram to predict the survival... 
Prognosis | Predictive accuracy | Nomogram | Triple negative breast cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
57. Full Text SARNP, a participant in mRNA splicing and export, negatively regulates E‐cadherin expression via interaction with pinin
by Kang, Gyeoung Jin and Park, Mi Kyung and Byun, Hyun Jung and Kim, Hyun Ji and Kim, Eun Ji and Yu, Lu and Kim, Boram and Shim, Jae Gal and Lee, Ho and Lee, Chang Hoon
Journal of Cellular Physiology, ISSN 0021-9541, 02/2020, Volume 235, Issue 2, pp. 1543 - 1555
Triple‐negative breast cancer (TNBC) is associated with a high mortality rate, which is related to the insufficient number of appropriate biomarkers and... 
epithelial–mesenchymal transition | pinin | mesenchymal phenotype | triple‐negative breast cancer | SARNP | E‐cadherin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
58. Full Text Metronomic combination of Vinorelbine and 5-Fluorouracil inhibit triple-negative breast cancer cells results from the proof of- concept VICTOR-0 study
by Cerrito, Maria Grazia and Pelizzoni, Davide and Bonomo, Sara Maria and Digiacomo, Nunzio and Scagliotti, Arianna and Bugarin, Cristina and Gaipa, Giuseppe and Grassilli, Emanuela and Lavitrano, Marialuisa and Giovannoni, Roberto and Bidoli, Paolo and Cazzaniga, Marina Elena
Oncotarget, 06/2018, Volume 9, Issue 44, pp. 27448 - 27459
5-fluorouracil | LC3A/B | Metronomic combination | Vinorelbine | Triple-negative breast cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
59. Full Text Impact of pre-diagnostic triglycerides and HDL-cholesterol on breast cancer recurrence and survival by breast cancer subtypes
by Lofterød, Trygve and Mortensen, Elin Synnøve and Nalwoga, Hawa and Wilsgaard, Tom and Frydenberg, Hanne and Risberg, Terje and Eggen, Anne Elise and McTiernan, Anne and Aziz, Sura Mohammed and Wist, Erik and Stensvold, Andreas and Reitan, Jon Brinchmann and Akslen, Lars A and Thune, Inger
ISSN 1471-2407, 2018
Background High triglycerides and low levels of high density lipoprotein (HDL)-cholesterol are observed to promote tumor growth. However, whether breast cancer... 
Lipids | Breast cancer | Molecular subtype | Survival | Triple negative breast cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
60. Full Text Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin
by Inao, Touko and Iida, Yuichi and Moritani, Tamami and Okimoto, Tamio and Tanino, Ryosuke and Kotani, Hitoshi and Harada, Mamoru
Oncotarget, ISSN 1949-2553, 05/2018, Volume 9, Issue 39, pp. 25545 - 25556
Breast cancers can be divided into several types. Because triple-negative breast cancer (TNBC) is the most refractory to current anti-cancer therapies,... 
Bcl-2 | Triple-negative | Breast cancer | Doxorubicin | ABT-199
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.